Peptonic Medical (publ) (“Peptonic”) is further strengthening its product portfolio with the launch of VagiVital Intimate Calming Gel, a specially formulated product designed to provide rapid relief from vaginal irritation, itching, burning, and discomfort during intimate contact. These symptoms can arise from various causes, including provoked vulvodynia (formerly known as vestibulitis). Recently granted a European patent, the product is intended for use on the external intimate area.
VagiVital Intimate Calming Gel is a tailored product that complements Peptonic’s existing range of clinically proven intimate care products. It has been expertly formulated to soothe, cool, and moisturize the external intimate area. The proprietary product is based on Peptonic’s AktivGel base, well-known for its documented moisturizing benefits. With its advanced formulation, VagiVital Intimate Calming Gel delivers immediate relief from irritation, burning, and itching, addressing common causes such as tight clothing, hygiene products, sanitary pads, and vulvodynia.
For more persistent symptoms, it is recommended to combine the use of VagiVital Intimate Calming Gel with VagiVital AktivGel to ensure deep and long-lasting hydration of the intravaginal area.
For further information, please contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic
PEPTONIC medical AB (publ) is a cutting-edge Swedish biomedical company, dedicated in the development and distribution of clinically proven self-care treatments and self-diagnostic tests in intimate women’s health. The portfolio is sold under the brands Vagivital and Vernivia.
The company’s vision is to revolutionize intimate health by empowering women to diagnose, treat, and prevent intimate medical conditions independently and effectively. Intimate health shall be natural, safe, and easy for women to manage on their own.
Central to Peptonic’s growth strategy is the geographical expansion of VagiVital and Vernivia through local partners. Peptonic Medical also intends to continuously broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company’s mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio.
The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense Marketing Inc in the USA and Peptonic Medical Ltd in Israel. Peptonic Medical was founded in 2009, and the company’s shares have been listed on the Spotlight Stock Market since 2014.
